Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation.

[16] In a Japanese trial that used low-dose (15 mg once daily) rivaroxaban (mean age of study population, 71 years), there was a strong trend for a reduction in the rate of stroke/systemic embolism with low dose rivaroxaban vs. warfarin (HR = 0.49; P = 0.050).

also in 5,725 other papers